Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-002396
Filing Date
2025-05-15
Accepted
2025-05-15 16:13:47
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8991
2 JOINT FILING AGREEMENT p25-1168exhibit99_1.htm EX-99.1 4524
  Complete submission text file 0000902664-25-002396.txt   15155
Mailing Address 632 BROADWAY SUITE 602 NEW YORK NY 10012
Business Address 632 BROADWAY SUITE 602 NEW YORK NY 10012 6469894000
Vestal Point Capital, LP (Filed by) CIK: 0001974915 (see all company filings)

EIN.: 922296021 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 245 MAIN STREET CAMBRIDGE MA 02142
Business Address 245 MAIN STREET CAMBRIDGE MA 02142 617-785-8308
Bicara Therapeutics Inc. (Subject) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94620 | Film No.: 25953193
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)